AIM News and Press, AIM ImmunoTech Inc. From 05/18/21

AIM ImmunoTech (AIM): Q1 GAAP EPS of -$0.08 in-line.Revenue of $0.02M (-60.0% Y/Y) misses by $0.33M.Cash, cash equivalents and marketable securities of $63.6M10QPress Release For further details see: AIM ImmunoTech EPS in-line, misses on revenue

OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021. As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to $54.4 million a...

OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets...

AIM ImmunoTech (AIM) has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.No serious adverse ...

OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious...

Upon completion of the dosing of Cohort 1 in a Phase 1 trial evaluating the safety of Ampligen as an intranasal therapy, AIM ImmunoTech (AIM) is moving to the dose escalation of Cohort 2 after reporting no serious adverse events.The Phase 1 trial involving 40 healthy subjects is a ‘cri...

OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving...

AIM ImmunoTech (AIM): FY GAAP EPS of -$0.45 misses by $0.02.Revenue of $0.16M (+14.3% Y/Y) misses by $0.31M.As of December 31, 2020, AIM had cash, cash equivalents and marketable securities of $54.4 million, compared with $8.8 million as of December 31, 2019.Press Release10K For further det...

OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. 2020 Financial Highlights As of December 31, 2020, AIM had cash, cash equivalents an...

OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park’s ongoing Phase 1/2a study e...